Invitae, Alnylam to Provide Free Genetic Testing for Primary Hyperoxaluria

Invitae announced today that it is partnering with RNAi therapeutics firm Alnylam Pharmaceuticals to provide free genetic testing to improve diagnosis and management of a rare inherited disorder called primary hyperoxaluria.

Genetic testing to gauge whether a person carries a mutation in the AGXT gene associated with the disease can confirm a suspected diagnosis and inform decision making.

Source: https://www.genomeweb.com/inherited-disease/invitae-alnylam-provide-free-genetic-testing-primary-hyperoxaluria